Depression: A Modifiable Risk Factor for Poor Outcomes in Fibromyalgia

Area of Science:

• Rheumatology
• Psychiatry
• Clinical Medicine

Background:

• Fibromyalgia affects approximately 40% of patients with depression.
• Antidepressants are recommended for fibromyalgia treatment by European Alliance of Associations for Rheumatology (EULAR) guidelines.

Purpose of the Study:

• To determine predictors of improved outcomes in fibromyalgia patients undergoing multicomponent treatment.
• To evaluate the prevalence of depression symptoms and their impact on functional outcomes post-treatment.

Main Methods:

• A longitudinal study involving 411 adult fibromyalgia patients at a tertiary care facility.
• Patients completed an intensive outpatient multicomponent treatment program including cognitive behavioral strategies.
• Functional status (FIQR) and depression (CES-D) were assessed pre- and post-treatment (approx. 5 months).

Main Results:

• A high prevalence of depressive symptoms was observed (73.2% at admission).
• Higher baseline depression scores predicted poorer outcomes after multicomponent treatment.
• Effective depression treatment led to improved functional outcomes at follow-up.

Conclusions:

• Depression is linked to poorer outcomes in fibromyalgia patients.
• Depression is a significant modifiable factor in fibromyalgia management.
• Guidelines should emphasize assessing and treating depression upon fibromyalgia diagnosis to enhance functional outcomes.